Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
APSTZD 2
- Development stage
- Unknown
- Lead developer
- Apsen Farmacêutica
- Administration
- Oral
01
Overview
**APSTZD 2** is an undisclosed investigational oral APSTZD treatment variant being developed by Apsen Farmacêutica for insomnia disorder. It is one of four APSTZD-labelled experimental interventions in the randomized, double-blind, double-dummy Phase II TINA study, which compares APSTZD variants with zolpidem extended-release and placebo in adults with chronic insomnia. The publicly available trial record does not disclose APSTZD 2's chemical identity, dose, formulation characteristics beyond oral tablets, or molecular mechanism of action.
Beyond the preview
Go deeper on APSTZD 2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on APSTZD 2.